250 related articles for article (PubMed ID: 33369716)
1. Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Chiou WR; Huang CC; Lin PL; Chuang JY; Liu LY; Su MI; Liao FC; Chen CY; Kuo JY; Tsai CT; Wu YJ; Lee YH
Am J Cardiovasc Drugs; 2021 Jul; 21(4):459-469. PubMed ID: 33369716
[TBL] [Abstract][Full Text] [Related]
2. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
Steinberg BA; Hellkamp AS; Lokhnygina Y; Halperin JL; Breithardt G; Passman R; Hankey GJ; Patel MR; Becker RC; Singer DE; Hacke W; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
Heart Rhythm; 2014 Jun; 11(6):925-32. PubMed ID: 24833235
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Wu VC; Wang CL; Huang YC; Tu HT; Huang YT; Huang CH; Chen SW; Kuo CF; Hung KC; Chang SH
Europace; 2023 May; 25(5):. PubMed ID: 37000581
[TBL] [Abstract][Full Text] [Related]
4. Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation.
Chiou WR; Lin PL; Huang CC; Chuang JY; Liu LY; Su MI; Liao FC; Kuo JY; Tsai CT; Wu YJ; Wang KT; Lee YH
Sci Rep; 2022 Mar; 12(1):3745. PubMed ID: 35260615
[TBL] [Abstract][Full Text] [Related]
5. Exploratory Evaluation of Rhythm Control by Dronedarone in Combination With Low-Dose Rivaroxaban, Warfarin, Antiplatelet, or None of the Antithrombotic Therapy in High-Risk Patients With Non-Permanent Atrial Fibrillation: A Retrospective Cohort Study.
Lin PL; Chiou WR; Su MI; Huang CC; Liao FC; Liu LY; Chuang JY; Chen CY; Tsai CT; Kuo JY; Yang TF; Wu YJ; Lee YH
Clin Appl Thromb Hemost; 2021; 27():10760296211052968. PubMed ID: 34894780
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
[TBL] [Abstract][Full Text] [Related]
7. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
Khachatryan A; Merino JL; de Abajo FJ; Botto GL; Kirchhof P; Breithardt G; Stambler B; Abenhaim L; Grimaldi-Bensouda L
Europace; 2022 Jul; 24(6):899-909. PubMed ID: 34792111
[TBL] [Abstract][Full Text] [Related]
8. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
[TBL] [Abstract][Full Text] [Related]
9. Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Holmes AP; Saxena P; Kabir SN; O'Shea C; Kuhlmann SM; Gupta S; Fobian D; Apicella C; O'Reilly M; Syeda F; Reyat JS; Smith GL; Workman AJ; Pavlovic D; Fabritz L; Kirchhof P
Heart Rhythm; 2021 Jul; 18(7):1212-1220. PubMed ID: 33737232
[TBL] [Abstract][Full Text] [Related]
10. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
[TBL] [Abstract][Full Text] [Related]
11. Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation.
Goehring EL; Bohn RL; Pezzullo J; Tave AK; Jones JK; Bozzi S; Tamayo RCSG; Sicignano N; Naccarelli GV
Am J Cardiol; 2020 Nov; 135():77-83. PubMed ID: 32861738
[TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Chun KJ; Byeon K; Im SI; Park KM; Park SJ; Kim JS; On YK
Clin Ther; 2014 Sep; 36(9):1169-75. PubMed ID: 25134972
[TBL] [Abstract][Full Text] [Related]
14. Dronedarone in high-risk permanent atrial fibrillation.
Connolly SJ; Camm AJ; Halperin JL; Joyner C; Alings M; Amerena J; Atar D; Avezum Á; Blomström P; Borggrefe M; Budaj A; Chen SA; Ching CK; Commerford P; Dans A; Davy JM; Delacrétaz E; Di Pasquale G; Diaz R; Dorian P; Flaker G; Golitsyn S; Gonzalez-Hermosillo A; Granger CB; Heidbüchel H; Kautzner J; Kim JS; Lanas F; Lewis BS; Merino JL; Morillo C; Murin J; Narasimhan C; Paolasso E; Parkhomenko A; Peters NS; Sim KH; Stiles MK; Tanomsup S; Toivonen L; Tomcsányi J; Torp-Pedersen C; Tse HF; Vardas P; Vinereanu D; Xavier D; Zhu J; Zhu JR; Baret-Cormel L; Weinling E; Staiger C; Yusuf S; Chrolavicius S; Afzal R; Hohnloser SH;
N Engl J Med; 2011 Dec; 365(24):2268-76. PubMed ID: 22082198
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Wu C; Tcherny-Lessenot S; Dai W; Wang Y; Kechemir H; Gandhi S; Lin S; Juhaeri J
Clin Ther; 2018 Mar; 40(3):450-455.e1. PubMed ID: 29500139
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the cost-effectiveness of dronedarone versus amiodarone, propafenone, and sotalol in patients with atrial fibrillation: results for Serbia.
Tesic D; Kostic M; Paunovic D; Jankovic SM
Kardiol Pol; 2015; 73(4):287-95. PubMed ID: 25428811
[TBL] [Abstract][Full Text] [Related]
17. Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Zhang P; Wang M; Liu W; Sun P; Cai S; Pan Y; Zhao Q
J Interv Card Electrophysiol; 2022 Jun; 64(1):121-127. PubMed ID: 35050451
[TBL] [Abstract][Full Text] [Related]
18. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation.
Ken-Opurum J; Srinivas SS; Park S; Charland S; Revel A; Preblick R
J Comp Eff Res; 2023 Aug; 12(8):e230065. PubMed ID: 37387403
[No Abstract] [Full Text] [Related]
20. Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Cay S; Kara M; Ozcan F; Ozeke O; Aksu T; Aras D; Topaloglu S
J Interv Card Electrophysiol; 2022 Nov; 65(2):381-389. PubMed ID: 35366133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
